In systemic sclerosis (SSc), a common and aetiologically mysterious form of scleroderma (defined as pathological fibrosis of the skin), previously healthy adults acquire fibrosis of the skin and viscera in association with autoantibodies 1 . Familial recurrence is extremely rare and causal genes have not been identified. Although the onset of fibrosis in SSc typically correlates with the production of autoantibodies, whether they contribute to disease pathogenesis or simply serve as a marker of disease remains controversial and the mechanism for their induction is largely unknown 2 . The study of SSc is hindered by a lack of animal models that recapitulate the aetiology of this complex disease. To gain a foothold in the pathogenesis of pathological skin fibrosis, we studied stiff skin syndrome (SSS), a rare but tractable Mendelian disorder leading to childhood onset of diffuse skin fibrosis with autosomal dominant inheritance and complete penetrance. We showed previously that SSS is caused by heterozygous missense mutations in the gene (FBN1) encoding fibrillin-1, the main constituent of extracellular microfibrils 3 . SSS mutations all localize to the only domain in fibrillin-1 that harbours an Arg-Gly-Asp (RGD) motif needed to mediate cell-matrix interactions by binding to cell-surface integrins 3 . Here we show that mouse lines harbouring analogous amino acid substitutions in fibrillin-1 recapitulate aggressive skin fibrosis that is prevented by integrin-modulating therapies and reversed by antagonism of the pro-fibrotic cytokine transforming growth factor b (TGF-b). Mutant mice show skin infiltration of pro-inflammatory immune cells including plasmacytoid dendritic cells, T helper cells and plasma cells, and also autoantibody production; these findings are normalized by integrin-modulating therapies or TGF-b antagonism. These results show that alterations in cell-matrix interactions are sufficient to initiate and sustain inflammatory and pro-fibrotic programmes and highlight new therapeutic strategies.
Fibrillin-1 contributes to the regulation of TGF-b, a cytokine that has been descriptively linked to many fibrotic diseases, including both SSS and SSc 3, 4 . TGF-b is secreted from the cell in the context of a large latent complex (LLC) that includes the active cytokine bound to a dimer of its processed amino-terminal propeptide, latency-associated peptide (LAP), which in turn binds to latent TGF-b-binding proteins (LTBPs) 5 . Studies in mouse models and in vitro have shown that fibrillin-1 interacts directly with LTBPs, allowing sequestration of the LLC by microfibrils 5 .
Mutations throughout the FBN1 gene also cause Marfan syndrome (MFS), a disorder characterized by bone overgrowth, ocular lens dislocation and aortic dilatation 6 . Failed matrix sequestration of the LLC in fibrillin-1-deficient patients and mice promotes increased activation of, and signalling by, TGF-b. SSS mutations are specifically localized to the fourth transforming growth factor-b-binding protein-like domain (TB4) of fibrillin-1, which encodes the RGD motif, through which fibrillin-1 binds integrins a v b 3 , a 5 b 1 and a v b 6 (refs 3, 5) .
To determine whether failed interaction between integrins and fibrillin-1 is sufficient to initiate skin fibrosis, two Fbn1-targeted knock-in mouse models were generated: one with SSS-associated change W1572C (the mouse equivalent of human W1570C) and the other with an RGD to RGE substitution (D1545E) predicted to cause an obligate loss of integrin binding to fibrillin-1 ( Supplementary Fig. 1 ). Mice heterozygous for either mutation phenocopy SSS with increased deposition of collagen by 1 month of age and a decrease in subcutaneous fat by 3 months of age ( Fig. 1 and Supplementary Fig. 2a, b ). Whereas homozygosity for D1545E causes embryonic lethality before embryonic day 10.5, mice homozygous for W1572C are viable and show accelerated skin fibrosis when compared with heterozygous littermates ( Fig. 1 and Supplementary Fig. 2a, b ). As seen in patients with SSS or SSc 3 , mutant mice show disorganized and excessive microfibrillar aggregates in the dermis, with sparsely distributed elastin ( Supplementary Fig. 2c ). Freshly isolated cells from mutant dermis show increased surface levels of integrins a 5 b 1 and a v b 3 in its active conformation (as assessed using WOW-1 antibody) by flow cytometry (Fig. 2a ). There was no corresponding increase in either total b 3 integrin or integrin b 5 , a subtype that can cross-react with WOW-1 ( Supplementary Fig. 3 ). On the basis of these data, we speculated that disrupted cell-matrix interaction in SSS might result in compensatory upregulation of specific integrins at the surface of dermal cells, and that integrins might represent a possible therapeutic target for this disease.
We next investigated whether mimicking integrin-matrix ligand (that is, fibrillin-1) interactions in mutant mice by using a b 1 integrinactivating antibody (b 1 aAb; 9EG7) offered therapeutic potential for the treatment of SSS. Treatment of SSS mouse models with b 1 aAb for 12 weeks normalized integrin expression, skin stiffness and distensibility and skin architecture ( Fig. 2a-c and Supplementary Fig. 4 ). In keeping with a pathogenic role for b 3 integrin, we found that targeted introduction of haploinsufficiency or the complete null state for the b 3 integrin gene (Itgb3) in SSS mice normalized skin stiffness, collagen deposition and subcutaneous fat by 3 months of age ( Supplementary  Fig. 5a, b ). By 5 months of age, 8 of 67 (12%) Itgb3-targeted animals developed focal dermal and epidermal thickening (irrespective of Fbn1 genotype) reminiscent of the aberrant wound-healing described previously in b 3 integrin-deficient mice ( Supplementary Fig. 5c) 7 .
To assess for a pathogenic contribution for TGF-b, SSS mice were treated for 12 weeks with a panspecific TGF-b-neutralizing antibody (TGF-bNAb; 1D11) or isotype-matched control IgG after establishment of dense fibrosis at 12 weeks of age. Clinical ( Fig. 3a ) and histological ( Fig. 3b ) findings confirmed full reversal of skin stiffness and restoration of skin architecture in TGF-bNAb-treated animals. Potential mechanisms for enhanced TGF-b activity include excessive concentration of latent TGF-b by the abnormally abundant microfibrillar aggregates in the dermis, or excessive integrin-mediated activation (release) of TGF-b from its latent complex 8 . To discriminate between these possibilities, we used flow cytometry to monitor mutant mice for increased cell-surface expression of the three integrin subtypes (a v b 5 , a v b 6 and a v b 8 ) known to support potent TGF-b activation 6 ; this was not observed ( Supplementary Fig. 6a ). In addition, immunofluorescence analysis of skin in mutant mice did not reveal increased expression of free TGF-b1 ( Supplementary Fig. 6b ), which is known to be activated by integrins through interaction with the RGD sequence in its LAP (LAP1). There was an increase in total (free and active) TGF-b2 ( Supplementary Fig. 6b ), which has not been shown to be activated by integrins (presumably as a result of the absence of an RGD sequence in LAP2) 6 . Furthermore, there was excessive concentration of both LAP1 and LAP2 in the dermis of mouse models of SSS, suggesting accumulation of the LLC for TGF-b1 and TGF-b2, respectively. Although we cannot exclude a contribution of integrin-mediated TGF-b activation, these data suggest that enhanced TGF-b bioavailability contributes prominently to increased TGF-b activity in mutant mice.
As seen in SSc, SSS mouse models show circulating anti-nuclear and anti-topoisomerase I antibodies ( Fig. 4a and Supplementary Fig. 7 ). The finding that the deep dermal fibrosis seen in early SSS ( Fig. 1 ) colocalizes with high expression of active b 3 integrin and accumulation of CD45 1 marrow-derived cells ( Supplementary Fig. 8a ) prompted speculation that an infiltrating class of immune cells might contribute to disease progression. In keeping with this hypothesis, nearly all dermal cells expressing high levels of a 5 b 1 and active b 3 integrins in SSS mice are CD317 1 plasmacytoid dendritic cells (pDCs) (Fig. 4b ). SSS mice show enrichment for cells that are CD11b 2 CD3 2 CD19 2 B220 1 SiglecH 1 Ly6C high in the dermis, further validating this identity ( Fig. 4b and Supplementary   Fig. 8b-d) 9 . As is characteristic of mature and active pDCs, these dermal cells express the pro-inflammatory cytokines interleukin (IL)-6 and interferon (IFN)-a ( Fig. 4c and Supplementary Fig. 8e ) 9 . There is also dermal polarization towards pro-inflammatory T helper (T H ) cell populations, including CD4 1 IL-4 1 T H 2, CD4 1 IL-17 1 T H 17 and CD4 1 IL-9 1 T H 9 cells ( Supplementary Fig. 9a, b ). In keeping with skewing towards T H 2, T H 9 and/or T H 17 cells, there was also an increased expression of IL-9, IL-13 and IL-22 by CD3 1 dermal cells (Supplementary Fig. 9a-c ). There was no corresponding increase in either IFN-c 1 CD4 1 T H 1 or FoxP3 1 CD4 1 T-regulatory (T reg ) cells in mutant animals ( Supplementary Fig. 9d ). Last, the dermis of SSS mice also showed infiltration with B220 high CD19 1 activated B cells and CD138 1 B220 low CD19 1 plasma cells ( Supplementary Fig. 10 ). These abnormalities, including circulating autoantibodies and immune cell infiltration and activation, were normalized by treatment of mutant mice with b 1 aAb ( Fig. 4 and Supplementary Figs 9 and 10 ). A similar response was seen in association with reversal of skin fibrosis on treatment with TGF-bNAb ( Supplementary Fig. 11 ).
We speculated that altered presentation of the fibrillin-1 RGD sequence might directly influence the expression of integrins by, and the performance of, pDCs. In keeping with this hypothesis, we found that wild-type spleen-derived pre-pDCs showed increased adherence and activation (expression of IFN-a and IL-6) when plated on the matrix expressed by SSS murine embryonic fibroblasts (MEFs) in comparison with control MEFs ( Supplementary Fig. 12 ).
SSc fibroblasts showed increased cell-surface presentation of total b 1 integrin ( Supplementary Fig. 13 ) and active b 3 integrin (as monitored by WOW-1 staining) in comparison with controls, whereas levels of total b 3 and b 5 integrins were normal ( Supplementary Fig. 14a ). Treatment with b 1 aAb TS2/16, which promotes and stabilizes integrin b 1 -ligand interactions, normalized cell-surface levels of active b 3 integrin (Supplementary Fig. 14a ). Treatment with b 3 integrin-blocking antibody (b 3 bAb) did not significantly decrease the cell-surface presentation of total b 1 integrin ( Supplementary Fig. 13 ). Human SSc cells in culture showed decreased levels of microRNA-29 (miR-29) ( Supplementary  Fig. 14b ), a small regulatory RNA that is repressed by TGF-b and is known to inhibit the expression of multiple matrix elements and to suppress fibrosis in selected disease states 10, 11 . Treatment with b 1 aAb normalized miR-29 expression and dose-dependently attenuated the expression of type I and type III collagen in SSc fibroblasts (Supplementary Fig. 14b ). SD208, an antagonist of the kinase activity of the type I TGF-b receptor subunit, also normalized the expression of collagen and miR-29a ( Supplementary Fig. 14c ).
In addition to canonical (Smad-dependent) signalling, TGF-b can also initiate so-called non-canonical cascades, prominently including extracellular signal-regulated kinase (ERK1/2) 5 . SSc fibroblasts showed normal TGF-b1-dependent phosphorylation of Smad3 (pSmad3) that was not influenced by integrin-modulating therapies, but uniquely showed TGF-b1-dependent phosphorylation of ERK1/2 (pERK1/2) in contrast with control fibroblasts that was normalized on treatment with either b 1 aAb or b 3 bAb ( Supplementary Fig. 14d, e ). The activation of ERK1/2 in SSc fibroblasts was seen within 5 min of stimulation with TGF-b1 and was inhibited by pretreatment with SD208, suggesting a relatively direct response ( Supplementary Fig. 14d, e ). In keeping with a pathogenic contribution of pERK1/2, treatment of SSc fibroblasts with U0126, an inhibitor of the mitogen-activated protein kinase/ ERK kinase (MEK), increased miR-29a levels and decreased collagen expression in SSc fibroblasts ( Supplementary Fig. 14f ). Both SSS mouse models showed excessive activation of ERK1/2 in CD317 1 pDCs and other dermal cells ( Supplementary Fig. 14g ). Treatment of Fbn1 D1545E/1 mice with the MEK inhibitor RDEA119 prevented skin stiffness, the accumulation of dermal collagen and the loss of subcutaneous fat ( Supplementary Fig. 14h , i).
This study shows that point mutations specifically in the sole integrinbinding domain of fibrillin-1 are sufficient to recapitulate the SSS phenotype in mice and to initiate many findings reminiscent of SSc, including LETTER RESEARCH dermal fibrosis, autoantibody production, high IFN-a expression, T H 2 and T H 17 polarization, and accumulation of activated B cells and plasma cells in the skin 1, 2, 4, 12, 13 . Although previous studies have reported autoantibodies and subdermal fibrosis in tight skin (Tsk) mice harbouring a large central duplication in Fbn1, there are no direct human correlates, and both the mechanism and pathogenic relevance remain unclear 14, 15 . In SSS, all of these processes can be functionally linked to altered integrin expression and/or function because they are prevented by integrin-modulating therapies. Although skin fibrosis was observed in mice on conditional silencing of b 1 integrin expression in keratinocytes 16 , targeting of Itgb1 in fibroblasts afforded relative protection against bleomycin-induced skin fibrosis 17 . This apparent discrepancy has not been explained mechanistically. A comparison of MFS and SSS highlights the complicated role of the extracellular matrix in cytokine regulation. Unlike MFS, in which a deficiency of fibrillin-1 is seen, SSS mutations promote the increased deposition of abnormal microfibrillar aggregates that fail to make contact with neighbouring cells but retain the ability to bind to the TGF-b LLC, findings also seen in SSc 3 . This results in a decreased or increased concentration of latent TGF-b in tissues in MFS or SSS, respectively 3, 5 . It is posited that in MFS a decreased concentration of LLC is offset by increased TGF-b activation but that this may occur in a tissue-specific manner 5, 6 . The relative deficiency of microfibrils and hence latent TGF-b in MFS would mandate continuing TGF-b production to support high signalling, whereas the high dermal concentration of TGF-b in SSS might allow a more sustained enhanced signalling state. Curiously, this does not seem to occur in all tissues in which fibrillin-1 is expressed, perhaps as a result of different repertoires of expressed integrin subtypes that vary in their sensitivity to conformational changes induced by SSS mutations, and/or tissue-specific Supplementary Fig. 16b ). For isotype control-treated animals, n 5 5 (Fbn1 1/1 ) and 7 (Fbn1 D1545E/1 ); for b 1 aAb-treated animals, n 5 4 (Fbn1 1/1 ) and 7 (Fbn1 D1545E/1 ). b, Clinical assessment demonstrated that b 1 aAb prevented skin stiffness in mutant animals when compared with those treated with an isotype-matched control (IgG). c, Masson's trichrome staining reveals decreased skin collagen and preservation of subcutaneous fat in b 1 aAb-treated mutants (left). Quantification of the thickness of the zones of dermal collagen and subcutaneous fat is shown (right). For isotype control-treated animals, n 5 12 (Fbn1 1/1 ), 9 (Fbn1 D1545E/1 ) and 8 (Fbn1 W1572C/1 ); for b 1 aAb-treated animals, n 5 12 (Fbn1 1/1 ), 10 (Fbn1 D1545E/1 ) and 10 (Fbn1 
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differences in the regulation of microfibrillar assembly. The stiffened ECM in SSS could support mechanical traction-based activation of the excessive amounts of latent TGF-b in the dermis, a plausible feedforward mechanism for the observed fibrosis 8 . Thus the level of TGF-b signalling in a given tissue may, at least in part, be determined by the integration of both positive and negative regulation by microfibrils 5, 6 .
Although the cell type that first detects and responds to aberrant presentation of the RGD sequence in fibrillin-1 remains unknown, it is useful to speculate on the involvement of pre-pDCs that normally perform a surveillance function for viral pathogens at low concentrations in the skin. Previous work has shown that a 5 b 1 integrin influences the adhesion, migration and maturation of DCs and that migration is inhibited by b 1 aAb, at least in part through podosome disassembly 18 . Furthermore, a specific role for a 5 b 1 integrin in pre-pDC chemotaxis and trafficking has been demonstrated 19 . It is therefore evident that pre-pDCs are informed by and respond to their matrix environment, with fibrillin-1 potentially serving as a prominent informant. In keeping with this, our in vitro observations ( Supplementary Fig. 12 ) suggest that an altered matrix environment, devoid of any systemic influence, is sufficient to promote pDC recruitment and activation. It remains to be determined whether this relates to the loss of a physiological inhibitory signal by normal microfibrils or to a pathogenic gain of function by abnormal microfibrillar aggregates seen in SSS and SSc.
pDCs are a major source of IFN-a and are capable of inducing T H 2 and T H 17 skewing, autoreactive B-cell and plasma-cell differentiation, and autoantibody production ( Supplementary Fig. 15 ) 9,12,20-22 ; they have also previously been implicated in multiple autoimmune processes (including SSc) 9,12,20-22 . Although pDCs can contribute to both tolerogenic T reg or auto-inflammatory T H 17 cell commitment, in vitro experiments suggest that TGF-b-treated pDCs favour the latter through a Smad-dependent mechanism 23 . Whereas the altered matrix environment in SSS probably contributes to excessive TGF-b activity early in the course of disease, TGF-b induces its own production and activation by pDCs, as well as IL-6 secretion (known prerequisites for T H 17 polarization) 23 . pDCs can also induce either T H 1 or T H 2 skewing through IL-6/IFN-a-dependent or OX40 ligand (OX40L)/ IL-4-dependent mechanisms, respectively ( Supplementary Fig. 15) 9 . pDCs in a T H 2 environment become activated and show enhanced IL-4 secretion, constituting a potential feedforward mechanism for maintenance of a T H 2 response 24 . In the context of high TGF-b signalling, this might also allow for T H 9 skewing 25 . Cytokines related to T H 2, T H 17 and pDCs, including IL-4, IL-6, IL-13, IL-17 and IFN-a, have been prominently implicated in the fibrotic response in various disease states, including SSc 1, 2, 4, 9, 12, 13, [20] [21] [22] . This study implicates TGF-b in pDC recruitment.
Although many studies have highlighted the contribution of integrins to fibrotic disease 8 , their focus has been on the ability of certain integrins to release (activate) TGF-b1 or TGF-b3 from the LLC through a direct interaction with RGD sequences in LAP1 and LAP3 (ref. 8) . Multiple observations in this study suggest that enhanced bioavailability of TGF-b, rather than its activation, may be the primary determinant of increased TGF-b activity in SSS and perhaps SSc. Our in vitro data in SSc fibroblasts suggest that cell-surface integrins can influence the inherent signalling properties of the TGF-b receptor complex in response to free and active TGF-b. Although the initiating pathogenic event in SSc remains unknown, this study provides evidence for a cell autonomous signalling defect that is maintained in culture. In theory, this could relate to primary but poorly penetrant genetic alterations or fixed epigenetic modifications, both of which may require a large environmental trigger. integrin-modulating therapies. a, Increased circulating levels of anti-nuclear and anti-topoisomerase I antibodies by enzyme-linked immunosorbent assay in Fbn1 D1545E/1 mice at 3 months of age are normalized on treatment with b 1 aAb but not when treated with an isotype-matched control (IgG). For isotype control-treated animals, n 5 6 (Fbn1 1/1 ), 4 (Fbn1 D1545E/1 ); for b 1 aAb-treated animals, n 5 4 (Fbn1 1/1 ), 10 (Fbn1 D1545E/1 ). b, The cells expressing high a 5 b 1 integrin in the dermis of mutant mice are CD317 high cells that fail to accumulate on treatment with b 1 aAb but not with an isotype-matched control (IgG).
b, c, The CD317 high cells that accumulate in the dermis of mutant mice are B220 1 CD3 2 CD19 2 plasmacytoid dendritic cells (b) and express both IFN-a and IL-6 (c). In b and c, for isotype control-treated animals, n 5 5 (Fbn1 1/1 ) and 7 (Fbn1 D1545E/1 ); for b 1 aAb-treated animals, n 5 4 (Fbn1 
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Activation of ERK1/2 has previously been implicated in the TGF-bmediated fibrotic response in general, and specifically in SSc fibroblasts [26] [27] [28] . It was previously observed 28 that constitutive ERK1/2 signalling in SSc fibroblasts drives the expression of integrin a v b 3 . Both a v b 3 and TGF-b were required for excessive collagen production. Despite overlapping observations and the common conclusion that a v b 3 represents an attractive therapeutic target, this study places ERK1/2 activation downstream of both TGF-b and enhanced active a v b 3 expression in SSc fibroblasts and shows phenotypic rescue in response to ERK antagonism in an in vivo model of scleroderma. Furthermore, we show prominent ERK1/2 signalling in pDCs in SSS mice, a described prerequisite for the stabilization, nuclear export and translation of IFN-a messenger RNA 29 , and for Toll-like receptor-mediated expression of inflammatory cytokines 30 . Whereas previous work associated low levels of miR-29, a negative regulator of collagen expression, with fibrotic diseases including post-injury cardiac fibrosis 10 and SSc 11 , this study offers a pathogenic sequence for scleroderma that integrates structural matrix elements, integrins, TGF-b signalling, ERK activation and miR-29.
SSS mouse models demonstrate the potential to reverse established dermal fibrosis, and they suggest several therapeutic strategies including b 1 integrin activation and blockade of signalling by b 3 integrin, TGF-b or ERK. When paired with the ability to perform preclinical trials in the first described mouse models of a genetically defined human presentation of scleroderma, the potential for therapeutic advancement seems promising.
METHODS SUMMARY
Subjects. Patients were recruited from the Scleroderma Center and Connective Tissue Clinic at Johns Hopkins Hospital. All skin biopsies and protocols were performed in compliance with the Johns Hopkins School of Medicine Institutional Review Board after informed consent. Mice. All mice were cared for in strict compliance with the Animal Care and Use Committee of the Johns Hopkins University School of Medicine. Fbn1 D1545E/1 and Fbn1 W1572C/1 mice were generated by homologous recombination. Itgb3 1/2 mice were purchased through Jackson Laboratories as heterozygotes. Skin biopsy, sera collection, enzyme-linked immunosorbent assay (ELISA), as well as histological and flow cytometric analysis and in vivo trials were performed as described in Methods. Cell culture. Primary human dermal fibroblasts were derived from skin biopsies from five patients with active diffuse systemic sclerosis and from six healthy controls. All antibodies and in vitro drug treatments and dosing, as well as methods for flow cytometric analyses, western blotting, RNA isolation and quantitative PCR are described in Methods. All details regarding co-culture of pDCs and murine embryonic fibroblasts are described in Methods. Statistics and graphs. All quantitative data are shown as standard boxplots produced in R statistical software. Statistical analysis was performed with a two-tailed t-test, assuming equal variance between the compared groups.
METHODS
Participants. Patients were recruited from the Scleroderma Center and Connective Tissue Clinic at Johns Hopkins Hospital (F.M.W. and H.C.D.). All skin biopsies and research protocols were performed in compliance with the Johns Hopkins School of Medicine Institutional Review Board and after informed consent. Mice. All mice were cared for in strict compliance with the Animal Care and Use Committee of the Johns Hopkins University School of Medicine. Fbn1 D1545E/1 and Fbn1 W1572C/1 mice were generated by homologous recombination as described in the next section. Itgb3 1/2 mice were purchased through Jackson Laboratories as heterozygotes. All experimental mice were on a mixed C57BL/6J and 129/SvEv background. To minimize potentially confounding background effects, all comparisons between genotypes and between treatment arms within a genotype were made between sex-matched littermates; no other randomization procedures were applied. Sample size estimates for the assessment of therapeutic responses were based on the penetrance and severity of the specific parameter under consideration in untreated cohorts. Generation of Fbn1 D1545E/1 and Fbn1 W1572C/1 mice. Fbn1 D1545E/1 and Fbn1 W1572C/1 mice were generated by homologous recombination (Supplementary Fig. 1a ). A 10-kilobase Fbn1 fragment was generated by PCR from mouse genomic tail DNA, digested with Acc65 and NheI restriction enzymes (NEB), and ligated into pSL301 (Invitrogen Corp.). Site-directed mutagenesis was performed with the QuikChange mutagenesis kit (Stratagene Inc.), creating either the D1545E or W1572C mutation. The targeting vector was assessed by sequence analysis. Site-directed mutagenesis was again performed to remove the AatII restriction site from pSL301. The NeoR cassette was amplified from pEGFP-C1 (Invitrogen Corp.) and the amplicon was subcloned into pCR2.1-TOPO (Invitrogen Corp.). A fragment containing the AatII restriction site and NeoR, with flanking loxP sequences, was subcloned into a unique AatII site in the Fbn1 intron before exon 38. The sequences of the loxP sites and site-directed mutagenesis-created mutations were confirmed by direct sequencing. The vector was linearized using a unique (NruI) site and electroporated into R1 embryonic stem cells. Positive clones were identified by Southern blot analysis ( Supplementary Fig. 1b ) as described previously 31 . Positive clones were injected into 129/SvEv blastocysts at embryonic day 3.5 and transferred into pseudopregnant females. Chimaeric offspring were mated to C57BL/6J mice, and germline transmission was observed for at least three independent targeting events for each genotype. All exons encompassed by and immediately flanking the targeting vector were analysed by sequencing of PCR-amplified genomic DNA derived from mutant animals to demonstrate the fidelity of targeting. Complete concordance of phenotype for three or two independent lines for mutations W1572C or D1545E, respectively, excluded any major off-target effect. Mice were genotyped on the basis of creation of a new AciI site (W1572C) or destruction of a BsmAI site (D1545E) in correctly targeted mice ( Supplementary Fig. 1c ). Primers used for amplification were 59-GATCCCACCACCTGCATC-39 (sense) and 59-CATGTG TTCACAGAAGGACAC-39 (antisense). The loxP-flanked NeoR was removed by breeding Fbn1 D1545E/1 and Fbn1 W1572C/1 mice with transgenic mice that ubiquitously expressed Cre recombinase using a EIIa promoter, purchased through Jackson Laboratories. More than 85 embryos were genotyped at embryonic day 10.5 for Fbn1 D1545E/1 homozygosity. In vivo drug treatment. All antibodies used to treat mice or cells were azide-free. Male mice were treated with b 1 integrin-activating antibody (b 1 aAb, Rat Clone 9EG7; special-ordered more than 98% pure and azide-free from BD Biosciences) or an isotype-matched control (Rat IgG2a, k; special-ordered more than 98% pure and azide-free from BD Biosciences) by intraperitoneal injection at 2 mg kg 21 every 5 days for 12 weeks, beginning at 1 month of age. Complete blood cell counts were performed to exclude pancytopenia in b 1 aAb-treated animals (Supplementary Fig. 16a ). For the TGF-b-neutralizing trial, 3-month-old male mice were treated with pan-specific TGF-b-neutralizing antibody (Mouse Clone 1D11, catalogue no. MAB1835; R&D) or an isotype control (Mouse IgG1, clone 11711, catalogue no. MAB002; R&D) by intraperitoneal injection at 10 mg kg 21 on alternate days for 12 weeks. RDEA119 was provided by C. J. Thomas, S. Patnaik and J. J. Marugan (National Institutes of Health Chemical Genomics Center). RDEA119 was reconstituted in 10% 2-hydroxypropyl-b-cyclodextrin (Sigma-Aldrich) dissolved in PBS, and was administered twice daily by oral gavage at a dose of 25 mg kg 21 . Treatment was initiated at 1 month of age and continued for 8 weeks. 2-Hydroxypropyl-b-cyclodextrin (10% in PBS) was administered as a control. Given the absolute concordance regarding pathology and therapeutic responses for Fbn1 D1545E/1 and Fbn1 W1572C/1 mice seen early in this study, later studies focused on Fbn1 D1545E/1 mice to limit the expense associated with in vivo antibody (TGF-bNAb and b 1 aAb) and drug (RDEA119) trials. Stiffness scoring. A clinical stiffness score was assigned by five observers blinded to genotype and treatment status. Mice were assessed in random order. A score of 1 indicates no stiffness (that is, identical to wild-type mice). A score of 4 indicates extreme stiffness based on previous experience with untreated SSS mice; 2 and 3 indicate a subjective assessment of an intermediate level of stiffness. Early in the course of studies, the same mice were assessed by the same observer on a different day. This pilot demonstrated excellent intra-observer concordance. To measure stretched skin area and total surface area, mice were anaesthetized with isoflurane, and the back skin was shaved and treated briefly with Nair cream. Area measurements were performed with NIH image J software (National Institutes of Health). Mice were then suspended briefly with forceps secured to the back skin by a clamp and photographed in profile in a uniform manner ( Supplementary Fig. 4a, b ). There were no differences in body weight between all experimental groups ( Supplementary Fig. 4c ). Histology. For tissue analysis, animals were killed with inhalational halothane (Sigma) or anaesthetized with isoflurane. Back skin was shaved and treated briefly with Nair cream before biopsy. Fixed skin was paraffin-embedded, sectioned, and stained with a standard Masson's trichrome stain. Dermal and subcutaneous fat thicknesses were measured under high-power fields as described previously 32 . Immunofluorescent staining was performed on frozen sections as described previously 33 . Active a v b 3 was detected with the WOW-1 antibody (gift from S. Shattil) and an anti-mouse Alexa Fluor-594 F(ab9) 2 fragment secondary antibody (catalogue no. A11020, Invitrogen). Other antibodies used included anti-CD45 antibody (catalogue no. 550539, BD), anti-Siglec H (catalogue no. 14-0333-81, ebiosciences) and antibodies against LAP1 (catalogue no. 141402, BioLegend), LAP2 (catalogue no. LS-C137100, Lifespan BioSciences), active TGF-b1 (Clone LC(1-30), gift from K. Flanders), and total TGF-b2 (catalogue no. ab66045, abcam). With the exception of WOW-1, all other antibodies were conjugated by means of an amine-based Alexa Fluor antibody labelling kit (catalogue nos A-20181, A20187, A-20185 and A-20186, Invitrogen). Electron microscopy. Electron microscopy was performed as described previously 34 . Enzyme-linked immunosorbent assay. Mouse sera were collected and enzymelinked immunosorbent assays (ELISAs) were performed with the Mouse Anti-Nuclear Antigens and Mouse Anti-Scl70kits (catalogue nos 5210 and 6110, AlphaDiagnostic) in accordance with the manufacturer's instructions. Cell culture. Primary human dermal fibroblasts were derived from skin biopsies from five patients with active diffuse systemic sclerosis and from six healthy controls. Biopsies were taken from the forearm and cultured as described previously 3 . All experiments were performed in cell lines at low (less than 5) passage. Primary MEFs were derived from embryonic day 13.5 embryos as described previously 35 . Murine pDCs were isolated from the spleens of wild-type C57Bl6/J mice by using the Plasmacytoid Dendritic Cell Isolation Kit II (catalogue no. 130-092-786, Miltenyi Biotec) and a midiMACS Separator (catalogue no. 130-042-302, Miltenyi Biotec) in accordance with the manufacturer's instructions. The pDC-containing cell suspensions routinely had more than 95% purity, as detected by flow cytometry. For MEF/pDC co-culture experiments, MEFs were cultured to complete confluence in culture medium containing RPMI 1640, 100 mg ml 21 streptomycin, 100 U ml 21 penicillin, 2 mM L-glutamine (Gibco) and 10% heat-inactivated fetal calf serum. At 72 h after confluence, 5 3 10 4 murine splenic pDCs ml 21 were plated onto MEF monolayers. After 72 h of co-culture, both adherent and non-adherent cellular fractions were harvested, counted, and analysed by flow cytometry. Flow cytometric analysis. Mouse skin was digested for flow cytometric analysis as described previously 36 . On average, 4 3 10 6 cells were obtained from a 1 3 2 cm 2 piece of skin for wild-type mice, and 8 3 10 6 cells were obtained from either SSS mouse model. Murine Fc receptors were blocked using antibodies against mouse CD16/32 antigens (catalogue no. 553141, BD Biosciences). Murine plasmacytoid dendritic cells were isolated as reported previously 37 . All isolated cells (including murine dermal cells, cultured MEFs, splenic murine pDCs or human dermal fibroblasts) were stained and fixed using the BD Cytofix/Cytoperm system (catalogue no. 554722, BD Biosciences). Data were acquired using CellQuest-Pro software on a FACSCalibur flow cytometer or BD FACSuite software on a FACSVerse flow cytometer (BD Biosciences). Data were analysed and all flow cytometry plots were contour plots (with outliers) that were generated with FlowJo software (TreeStar). For histograms, FlowJo software divides all events into 256 'bins', which are numerical ranges for the parameter on the x axis. The percentage of maximum (y axis) is the number of cells in each bin divided by the number of cells in the bin that contains the largest number of cells. Gating for live cells was based on staining with the LIVE/DEAD Fixable Dead Cell Stain Kit (catalogue no. L34955, Invitrogen). All staining was performed with fluorophore-conjugated primary and isotype control antibodies. All antibodies were either purchased as fluorochrome conjugates or conjugated by means of amine-based Alexa Fluor antibody labelling kits (catalogue nos A-20181, A20187, A-20185 and A-20186, Invitrogen). Mouse and human active a v b 3 was detected with fluorophore-conjugated WOW-1 antibody (gift from S. Shattil). EDTA (10 mM) and 2 mM MnCl 2 were used as negative and positive controls, respectively, for a v b 3 activation in flow cytometry experiments ( Supplementary Fig. 16b) 38, 39 . Integrin a v b 5 , a subtype known to react with the WOW-1 antibody 39 , was monitored in mouse and human LETTER RESEARCH
